AR118839A1 - Formas sólidas de un inhibidor de glyt1 - Google Patents
Formas sólidas de un inhibidor de glyt1Info
- Publication number
- AR118839A1 AR118839A1 ARP200101242A ARP200101242A AR118839A1 AR 118839 A1 AR118839 A1 AR 118839A1 AR P200101242 A ARP200101242 A AR P200101242A AR P200101242 A ARP200101242 A AR P200101242A AR 118839 A1 AR118839 A1 AR 118839A1
- Authority
- AR
- Argentina
- Prior art keywords
- ppm
- solid forms
- solid
- inhibitor
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formas sólidas de un inhibidor del transportador de glicina-1 (GlyT1). También métodos para fabricar estas formas sólidas, composiciones farmacéuticas que comprenden estas formas sólidas y su uso para afecciones médicas que responden al tratamiento con un inhibidor del transportador de glicina-1. Reivindicación 1: Una Forma sólida I del Compuesto 1 que tiene la fórmula estructural (1) en donde la Forma I del Compuesto 1 caracterizada porque: al menos tres picos de XRPD en 2Q ángulos seleccionados de 4,6º, 10,0º, 16,7º, 18,0º, 19,0º, 20,0º y 22,7º; o al menos tres picos de resonancia magnética nuclear de ¹³C en estado sólido en los desplazamientos químicos seleccionados de 131,5 ppm, 127,2 ppm, 28,7 ppm y 25,7 ppm; o al menos tres picos de resonancia magnética nuclear de ¹⁹F en estado sólido en los desplazamientos químicos seleccionados de -64,3, -64,8, -65,9, -66,8, -78,0, -78,5, -79,3 y -80,0 ppm.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841401P | 2019-05-01 | 2019-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118839A1 true AR118839A1 (es) | 2021-11-03 |
Family
ID=70740812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101242A AR118839A1 (es) | 2019-05-01 | 2020-04-30 | Formas sólidas de un inhibidor de glyt1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11447474B2 (es) |
| EP (1) | EP3962911A1 (es) |
| JP (1) | JP2022530630A (es) |
| KR (1) | KR20220004174A (es) |
| CN (1) | CN113784966A (es) |
| AR (1) | AR118839A1 (es) |
| AU (1) | AU2020266566A1 (es) |
| BR (1) | BR112021020883A2 (es) |
| CA (1) | CA3138288A1 (es) |
| CL (1) | CL2021002837A1 (es) |
| CO (1) | CO2021014260A2 (es) |
| CR (1) | CR20210545A (es) |
| DO (1) | DOP2021000224A (es) |
| EA (1) | EA202192925A1 (es) |
| EC (1) | ECSP21082195A (es) |
| IL (1) | IL287630A (es) |
| JO (1) | JOP20210295A1 (es) |
| MA (1) | MA55801A (es) |
| MX (1) | MX2021013341A (es) |
| PE (1) | PE20212263A1 (es) |
| SG (1) | SG11202111972YA (es) |
| TW (1) | TW202106680A (es) |
| WO (1) | WO2020223419A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| WO2021142329A1 (en) | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| JP2023537963A (ja) * | 2020-08-13 | 2023-09-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 統合失調症に伴う認知機能障害に対する処置法 |
| WO2022078927A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| WO2005037216A2 (en) * | 2003-10-14 | 2005-04-28 | Pfizer Products Inc. | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| AU2009322420A1 (en) * | 2008-12-04 | 2011-06-23 | Sanofi | Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative |
| WO2010078348A1 (en) * | 2008-12-29 | 2010-07-08 | Vanderbilt University | 3.1.0 bicyclic glyt1 inhibitors and methods of making and using same |
| US9012489B2 (en) * | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| RU2768473C2 (ru) * | 2017-04-27 | 2022-03-24 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение |
-
2020
- 2020-04-30 JO JOP/2021/0295A patent/JOP20210295A1/ar unknown
- 2020-04-30 DO DO2021000224A patent/DOP2021000224A/es unknown
- 2020-04-30 CA CA3138288A patent/CA3138288A1/en active Pending
- 2020-04-30 CR CR20210545A patent/CR20210545A/es unknown
- 2020-04-30 BR BR112021020883A patent/BR112021020883A2/pt unknown
- 2020-04-30 US US16/862,608 patent/US11447474B2/en active Active
- 2020-04-30 EA EA202192925A patent/EA202192925A1/ru unknown
- 2020-04-30 KR KR1020217039503A patent/KR20220004174A/ko unknown
- 2020-04-30 TW TW109114685A patent/TW202106680A/zh unknown
- 2020-04-30 PE PE2021001800A patent/PE20212263A1/es unknown
- 2020-04-30 WO PCT/US2020/030580 patent/WO2020223419A1/en active Application Filing
- 2020-04-30 JP JP2021563717A patent/JP2022530630A/ja active Pending
- 2020-04-30 CN CN202080032902.7A patent/CN113784966A/zh active Pending
- 2020-04-30 MX MX2021013341A patent/MX2021013341A/es unknown
- 2020-04-30 AU AU2020266566A patent/AU2020266566A1/en active Pending
- 2020-04-30 EP EP20726654.5A patent/EP3962911A1/en active Pending
- 2020-04-30 SG SG11202111972YA patent/SG11202111972YA/en unknown
- 2020-04-30 AR ARP200101242A patent/AR118839A1/es unknown
- 2020-04-30 MA MA055801A patent/MA55801A/fr unknown
-
2021
- 2021-10-26 CO CONC2021/0014260A patent/CO2021014260A2/es unknown
- 2021-10-27 IL IL287630A patent/IL287630A/en unknown
- 2021-10-28 CL CL2021002837A patent/CL2021002837A1/es unknown
- 2021-11-17 EC ECSENADI202182195A patent/ECSP21082195A/es unknown
-
2022
- 2022-06-27 US US17/849,935 patent/US20220332710A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021014260A2 (es) | 2021-10-29 |
| PE20212263A1 (es) | 2021-11-29 |
| DOP2021000224A (es) | 2021-12-15 |
| IL287630A (en) | 2021-12-01 |
| CN113784966A (zh) | 2021-12-10 |
| US11447474B2 (en) | 2022-09-20 |
| ECSP21082195A (es) | 2021-12-30 |
| WO2020223419A1 (en) | 2020-11-05 |
| MA55801A (fr) | 2022-03-09 |
| BR112021020883A2 (pt) | 2022-04-19 |
| EA202192925A1 (ru) | 2022-03-23 |
| SG11202111972YA (en) | 2021-11-29 |
| TW202106680A (zh) | 2021-02-16 |
| KR20220004174A (ko) | 2022-01-11 |
| JOP20210295A1 (ar) | 2023-01-30 |
| US20200347041A1 (en) | 2020-11-05 |
| AU2020266566A1 (en) | 2021-11-11 |
| CL2021002837A1 (es) | 2022-07-29 |
| JP2022530630A (ja) | 2022-06-30 |
| US20220332710A1 (en) | 2022-10-20 |
| CA3138288A1 (en) | 2020-11-05 |
| MX2021013341A (es) | 2021-11-17 |
| EP3962911A1 (en) | 2022-03-09 |
| CR20210545A (es) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118839A1 (es) | Formas sólidas de un inhibidor de glyt1 | |
| CL2020003102A1 (es) | Molécula que tiene utilidad pesticida, y composiciones y procedimientos relacionados con la misma. | |
| BR112015022456A2 (pt) | síntese de líquidos iônicos de compostos derivados de lignina | |
| AR087715A1 (es) | Anticuerpos anti pcsk9 y usos de los mismos | |
| DOP2010000323A (es) | Pirimidin-5-carboxamidas sustituidas 281 | |
| CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
| CO6700838A2 (es) | Compuestos sustituidos de banzamida | |
| CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
| AR087909A1 (es) | Composiciones farmaceuticas | |
| AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| UY34008A (es) | ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?. | |
| CL2018000996A1 (es) | Sistemas y procedimientos para retención de fluidos en superficie. | |
| MX2018003273A (es) | Copolimero para usarse como aditivo detergente para combustible. | |
| NZ726947A (en) | Molecules having certain pesticidal utilities, intermediates, compositions, and processes, related thereto | |
| UY36574A (es) | Inhibidores de bromodominios | |
| AR065896A1 (es) | Formas cristalinas de [3-(4-{2 butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]dietil-amina | |
| CL2018001407A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| CL2018002670A1 (es) | Composición de componentes múltiples para producir un hidrogel inhibidor de la corrosión | |
| BR112014000697A2 (pt) | processo e éster vinílico | |
| CL2019001623A1 (es) | Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor. | |
| MX359556B (es) | Acido 2-[5-[n-(4-fluorofenil)carbamoíl]pirimidin-2-ilsulfanilmetil ]-4-(trifluorometoxi)fenil]borónico. | |
| DE602006005693D1 (de) | Turbomaschinenverdichter | |
| PE20160849A1 (es) | Formulaciones de inyeccion con base en aceite de sesamo | |
| EA201500438A1 (ru) | Кристаллическая фаза (3s,3s')-4,4'-дисульфандиил-бис-(3-аминобутан-1-сульфокислоты) с l-лизином |